TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22040504
Drug: Lianhuaqingwen capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhuaqingwen capsule (LHC)
Study: 19453758
Drug: Silymarin (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (140 mg three times a day) plus desferrioxamine
Study: 11471852
Drug: Imidapril 5
Normalized name: imidapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 5 ‐ 10 mg/day
Study: 11471852
Drug: Nifedipine SR
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine SR 20 ‐ 40 mg twice daily
Study: 3348161
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ferrous sulfate.kg‐1.d‐1 for 12 weeks
Study: 23820968
Drug: Sham subcutaneous
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham subcutaneous injection of sterile saline
Study: 17058517
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily (n = 90)
Study: 17058517
Drug: Pantoprazole 40
Normalized name: pantoprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 40 mg once daily (n = 90)
Study: 9716056
Drug: Ciprofloxacin suspension
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin suspension (10 mg/kg every 12 h for 5 days, maximum individual dose 500 mg)
Study: 9716056
Drug: Pivmecillinam tablets
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam tablets (15-20 mg/kg every 8 h for 5 days, maximum individual dose 300 mg)
Study: 11099086
Drug: Ciprofloxacin suspension
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin suspension
Study: 9716056
Drug: Pivmecillinam tablets
DrugBank: Pivmecillinam (DB01605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam tablets
Study: 7979041
Drug: Displaced view
Approvals — FDA: no, EMA: no, PMDA: no
Description: Displaced view with inflated implants
Study: 7979041
Drug: Deflated adjustable
Normalized name: panthenol
DrugBank: Panthenol (DB11204)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflated adjustable implants
Study: 2722728
Drug: cefoxitin sodium
Normalized name: Cefoxitin Sodium
DrugBank: Cefoxitin (DB01331)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefoxitin sodium (30 mg/kg)
Study: 2722728
Drug: cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefmetazole sodium (15 mg/kg)
Study: 2722728
Drug: cefmetazole sodium
Normalized name: Cefmetazole Sodium
DrugBank: Cefmetazole (DB00274)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefmetazole sodium (30 mg/kg)
Study: 48347
Drug: Hydromorphone 0.5
Normalized name: HYDROMORPHONE 0.5MG/ML INJ,30ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.5 mg
Study: 31307524
Drug: UGSJB granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGSJB granule with acupuncture, twice daily
Study: 31307524
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with acupuncture, twice daily
Study: 26135463
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (cIV) of 160 mg furosemide for 16 h/day (n=15)
Study: 26135463
Drug: Bolus injections
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injections (bI) of 80 mg furosemide twice a day (n=14)
Study: 26135463
Drug: Furosemide plus
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide plus hypertonic saline solution (HSS) as an infusion for 30 min once a day (n=14)
Study: 23066720
Drug: Methotrexate (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.4 mg/kg weekly)
Study: 23066720
Drug: Acitretin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (0.5 mg/kg daily)
Study: 10855154
Drug: Home-based preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based preoperative bowel preparation with home care services
Study: 10855154
Drug: Home-based preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based preoperative bowel preparation without home care services
Study: 10855154
Drug: Hospital-based preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based preoperative bowel preparation
Study: 9096986
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS (5, 20, 40, or 60 mg)
Study: 9096986
Drug: Glipizide GITS
Normalized name: Glipizide
DrugBank: Glipizide (DB01067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glipizide GITS (5, 10, 15, or 20 mg)
Study: 8467308
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment and teaching programme (4 group sessions conducted by paramedical personnel)
Study: 8467308
Drug: Structured treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured treatment and teaching programme
Study: 30882137
Drug: Short-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course therapy (median, 9 days; IQR, 8-10)
Study: 30882137
Drug: Long-course therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-course therapy (median, 16 days; IQR, 14-17)
Study: 18420531
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg every 2 weeks
Study: 18420531
Drug: Pegloticase 8
Normalized name: pegloticase 8 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase 8 mg every 4 weeks
Study: 24447425
Drug: Pegloticase (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (both dosing cohorts)
Study: 22791906
Drug: Oral cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cannabis extract (CE) 25 mg daily after titration
Study: 16981900
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg montelukast daily for 6 days
Study: 16049631
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment and counseling with a self-help guide for 7 weeks
Study: 10071523
Drug: NADH (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NADH (10 mg)
Study: 7174213
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment with short-wave diathermy and daily exercises with graduated weights
Study: 15085090
Drug: Ethanol influx
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol influx (40 g bolus infusion)
Study: 10436958
Drug: Xuezhikang (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang (4 capsules/day, 1.2 g/day for 8 weeks)
Study: 10436958
Drug: Simvastatin (Zocor,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (Zocor, 10 mg/day for 8 weeks)
Study: 7635024
Drug: Routine iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine iron supplements during pregnancy
Study: 7635024
Drug: No iron
Normalized name: No Iron Multivitamin with Minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: No iron supplements during pregnancy
Study: 27856432
Drug: Sarilumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarilumab (200 mg every 2 weeks)
Study: 26473625
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every 2 weeks)
Study: 25604769
Drug: ω3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω3 plus low‐dose aspirin for 6 months
Study: 19332209
Drug: Adenosine or
Normalized name: adenosine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine or regadenoson administration
Study: 16968790
Drug: Systemic nonselective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic nonselective COX inhibition (100 mg indomethacin)
Study: 16968790
Drug: Selective COX-2
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective COX-2 blockade (200 mg celecoxib)
Study: 16968790
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (8 mg/min.dl)
Study: 16968790
Drug: L-NMMA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (100 microg/min.dl)
Study: 15517116
Drug: Naltrexone 50
Normalized name: naltrexone 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone 50 to 150 mg daily
Study: 11393553
Drug: 4 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 days intravenous insulin infusion annually followed by b.i.d. low doses of subcutaneous ultralente insulin
Study: 2885639
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose polymer solution (302 mOsm/kg)
Study: 2885639
Drug: 1.36% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.36% glucose solution (332 mOsm/kg)
Study: 2885639
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose polymer solution
Study: 26791478
Drug: Kundalini yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kundalini yoga programme (15min twice-daily for 12 weeks)
Study: 22620695
Drug: Spinosad at
Normalized name: Spinosad
DrugBank: Spinosad (DB08823)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spinosad at the manufacturer's recommended dose
Study: 17126403
Drug: Dorzolamide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide treatment
Study: 11996471
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin/etoposide (PE) followed by hyperfractionated accelerated radiotherapy (HF-RTx; 1.5 Gy bid up to a total dose of 45 Gy in 3 weeks) concurrent with one cycle of PE, and a small volume boost of 20 Gy (qd) for a total of 65 Gy to the primary.
Study: 2676249
Drug: Normal sodium
Normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal sodium intake group (44 subjects receiving less than 80 mmol sodium daily in the diet plus 80 mmol of sodium supplement as eight slow release sodium chloride tablets daily)
Study: 2676249
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium intake group (44 subjects receiving less than 80 mmol sodium daily in the diet plus eight slow release sodium chloride placebo tablets daily)
Study: 24357
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam via deep intramuscular injection
Study: 24357
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lorazepam via deep intramuscular injection
Study: 24357
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg lorazepam via intravenous injection
Study: 24357
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg lorazepam via intravenous injection
Study: 24357
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg and 4 mg lorazepam via any route
Study: 30335625
Drug: 0.050 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.050 μg · kg(‐1) · min(‐1) norepinephrine infusion
Study: 30335625
Drug: 0.075 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.075 μg · kg(‐1) · min(‐1) norepinephrine infusion
Study: 30335625
Drug: 0.025 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025 μg · kg(‐1) · min(‐1) norepinephrine infusion (control)
Study: 25754162
Drug: Once daily
Normalized name: GEL, ONCE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily dose of oral isotretinoin
Study: 25754162
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily dose of oral isotretinoin
Study: 25754162
Drug: Both regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both regimens of oral isotretinoin
Study: 21546612
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg once daily for 90 days)
Study: 21546612
Drug: Endothelial antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial antioxidant compound (EAC) administration after tadalafil discontinuation for 6 months
Study: 21546612
Drug: No other
Approvals — FDA: no, EMA: no, PMDA: no
Description: No other treatment during follow-up after tadalafil cessation
Study: 15066454
Drug: Daily 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 150 IU recombinant hFSH
Study: 7739942
Drug: Generic slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic slow-release theophylline tablet
Study: 21692673
Drug: Antiviral drug
Normalized name: antiviral drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral drug therapy
Study: 31821732
Drug: Olaratumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaratumab (15 mg/kg) + Doxorubicin (75 mg/m2)
Study: 31821732
Drug: Olaratumab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaratumab (20 mg/kg) + Doxorubicin (75 mg/m2)
Study: 25962070
Drug: Sparkling white
Normalized name: Sparkling white wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparkling white wine (340 mL; 30 g alcohol) in unpleasant ambiance
Study: 25962070
Drug: Sparkling white
Normalized name: Sparkling white wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparkling white wine (340 mL; 30 g alcohol) in pleasant ambiance
Study: 25962070
Drug: Alcohol-free sparkling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free sparkling white wine (340 mL; <2 g alcohol) in unpleasant ambiance
Study: 25962070
Drug: Alcohol-free sparkling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol-free sparkling white wine (340 mL; <2 g alcohol) in pleasant ambiance
Study: 21520432
Drug: High-frequency oscillatory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency oscillatory ventilation (HFOV) plus inhaled nitric oxide (iNO)
Study: 21520432
Drug: Pressure-controlled assist/control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure-controlled assist/control ventilation (PCACV) plus inhaled nitric oxide (iNO)
Study: 18579510
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg mifepristone every other day for 3 months
Study: 18261860
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment for alcohol dependence
Study: 11480805
Drug: Target-absent photo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target-absent photo lineup administered by interviewers who were misinformed about the thief's position.
Study: 29638147
Drug: 20 mEq
Normalized name: potassium chloride 20 MEQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mEq magnesium L-lactate dihydrate under fasting conditions
Study: 29638147
Drug: 20 mEq
Normalized name: potassium chloride 20 MEQ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mEq magnesium L-lactate dihydrate under fed conditions
Study: 29638147
Drug: IV infusion
Normalized name: IV INFUSION SET (WINTHROP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of 20 mEq magnesium sulfate
Study: 27533046
Drug: Pre-existing anti-Vi
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-existing anti-Vi antibody
Study: 11781912
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg droperidol intramuscularly
Study: 11781912
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg meperidine intramuscularly
Study: 9831973
Drug: Fenofibrate (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (300 mg daily)
Study: 9831973
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg daily)
Study: 8208098
Drug: Thyropol (thyroid-releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyropol (thyroid-releasing hormone film)
Study: 2734721
Drug: Ornidazole administered
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole administered by one daily IV infusion at 20 mg/kg
Study: 2734721
Drug: Ornidazole administered
Normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornidazole administered by two daily IV infusions at 20 mg/kg
Study: 31948990
Drug: TKR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKR plus 12 weeks of supervised non-surgical treatment (exercise, education, diet, insoles and pain medication)
Study: 29723634
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment alone
Study: 31948990
Drug: TKR plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKR plus non-surgical treatment
Study: 30900905
Drug: Buccal dissolution
Normalized name: Witch Hazel 30 mg in 30 mL TOPICAL PATCH [LEADERS INSOLUTION COCONUT LIFTING RECOVERY MASK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal dissolution test with polymer coatings (Surelease:Opadry at 8, 12, and 16% weight gain; Opadry EC at 4, 6, and 8% weight gain; Kollicoat Smartseal 100P at 10% weight gain)
Study: 12460133
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment control (DTC)
Study: 21554549
Drug: udenafil 100
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: udenafil 100 mg
Study: 21083516
Drug: Enoxaparin T
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin T (40 mg daily for 7 days)
Study: 21083516
Drug: Enoxaparin R
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin R (40 mg daily for 7 days)
Study: 11205424
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections (two injections separated by 15 min)
Study: 9272133
Drug: CHOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (standard therapy)
Study: 8511091
Drug: HDCV 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV 2 injections (days 0 and 28)
Study: 8511091
Drug: HDCV 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDCV 3 injections (days 0, 7, and 28)
Study: 8511091
Drug: PVRV 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV 2 injections (days 0 and 28)
Study: 8511091
Drug: PVRV 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVRV 3 injections (days 0, 7, and 28)
Study: 8511091
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose at 1 year
Study: 3493614
Drug: Propofol 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.5 mg X kg‐1
Study: 3493614
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg X kg‐1
Study: 16377282
Drug: Morning intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning intake of atorvastatin
Study: 16377282
Drug: Evening intake
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening intake of atorvastatin
Study: 11314241
Drug: Mud bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud bath treatment (group A)
Study: 11314241
Drug: Bath treatment
Normalized name: Aveeno Soothing Bath Treatment
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bath treatment alone (group B)
Study: 30509675
Drug: Cefiderocol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol (2 g) administered intravenously three times daily for 7-14 days
Study: 30509675
Drug: Imipenem-cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (1 g each) administered intravenously three times daily for 7-14 days
Study: 30509675
Drug: Cefiderocol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefiderocol (2 g)
Study: 30509675
Drug: Imipenem-cilastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem-cilastatin (1 g each)
Study: 28076940
Drug: Iso sorbide
Normalized name: iso-sulfan blue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iso sorbide mononitrate (ISMN) 60 mg sustained release, self-administered vaginally every other day for five doses
Study: 28076940
Drug: Pyridoxine 10
Normalized name: pyridoxine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxine 10 mg (control)
Study: 22257581
Drug: i.v. 1
Normalized name: Monistat I.V. 10 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. 1 mg tolvaptan
Study: 22257581
Drug: oral 30
Normalized name: Aloral 300 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral 30 mg tolvaptan
Study: 8514071
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean dose in vasovagal group)
Study: 8514071
Drug: Midazolam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (mean dose in control group)
Study: 392375
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: decontaminated by nonabsorbable antibiotics in strict reverse isolation
Study: 21461596
Drug: PGE(1) infusion
Normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PGE(1) infusion (2.5 ng/kg/min) for 4 weeks
Study: 17198774
Drug: N-acetylcysteine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (600 mg orally the day before and the morning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine before skin incision, followed by perfusion at 12.5 mg x kg(‐1) x h(‐1) over 24 hours; n = 50)
Study: 14987884
Drug: Procalcitonin-guided treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin-guided treatment (n=124)
Study: 9764348
Drug: Heparin/Aspirin (H/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Aspirin (H/A) not administered
Study: 9764348
Drug: Heparin/Aspirin (H/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin/Aspirin (H/A) with Intravenous Immunoglobulin G (IVIg)
Study: 31611626
Drug: Intensive block-based
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive block-based chemotherapy (for slow responders with MRD > 0.1% on day 29)
Study: 31611626
Drug: Intensive block-based
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive block-based chemotherapy
Study: 31611626
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (both arms)